Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $15.45 in the prior trading day, Nurix Therapeutics Inc (NASDAQ: NRIX) closed at $14.19, down -8.16%. In other words, the price has decreased by -$8.16 from its previous closing price. On the day, 1.29 million shares were traded.
Ratios:
Our goal is to gain a better understanding of NRIX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.46 and its Current Ratio is at 6.46. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on December 10, 2024, initiated with a Buy rating and assigned the stock a target price of $35.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $35.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $35.UBS initiated its Buy rating on October 24, 2024, with a $35 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 03 ’25 when van Houte Hans sold 5,825 shares for $14.49 per share. The transaction valued at 84,388 led to the insider holds 33,724 shares of the business.
JOHANNES VAN HOUTE bought 5,825 shares of NRIX for $89,996 on Mar 03 ’25. On Jan 31 ’25, another insider, Ring Christine, who serves as the Chief Legal Officer of the company, sold 5,760 shares for $19.95 each. As a result, the insider received 114,934 and left with 32,538 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 19.74 while its Price-to-Book (P/B) ratio in mrq is 2.04.
Stock Price History:
Over the past 52 weeks, NRIX has reached a high of $29.56, while it has fallen to a 52-week low of $11.90. The 50-Day Moving Average of the stock is -23.88%, while the 200-Day Moving Average is calculated to be -32.36%.
Shares Statistics:
A total of 75.87M shares are outstanding, with a floating share count of 74.37M. Insiders hold about 2.00% of the company’s shares, while institutions hold 108.08% stake in the company.
Earnings Estimates
The market rating of Nurix Therapeutics Inc (NRIX) is currently shaped by the ongoing analysis conducted by 13.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.76, with high estimates of -$0.55 and low estimates of -$0.94.
Analysts are recommending an EPS of between -$2.42 and -$3.82 for the fiscal current year, implying an average EPS of -$3.09. EPS for the following year is -$3.13, with 11.0 analysts recommending between -$1.62 and -$4.78.
